Pancreatic cancer;Karcinom pankreatu

Gastroenterologie a Hepatologie

Volumn 66, Issue 5, 2012, Pages 350-356

  Hucl, Tomáš ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Ethiology; Pancreatic neoplasms; Signalling pathway; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CHRONIC PANCREATITIS; DNA DAMAGE; HUMAN; OBESITY; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; SMOKING;

EID: 84870017256     PISSN: 18047874     EISSN: 1804803X     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20(2): 197-209.
2. Saglova A, Spicak J, Hucl T. Karcinom pankreatu: Molekulá rní biologie a časnádiagnostika. Prak Lék 2010; 90: 489-493.
3. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6(12): 699-708.
4. Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134(1): 95-101. (Pubitemid 350309328)
5. Almoguera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-Kras genes. Cell 1988; 53(4): 549-554.
6. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8(1): 27-32. (Pubitemid 24274057)
7. Schutte M, Hruban RH, Geradts J et al. Abrogation of the Rb/p16 tumor-supressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57(15): 3126-3130. (Pubitemid 27351723)
8. Hanh SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271(5247): 350-353.
9. Goggins M, Shekher M, Turnacioglu K et al. Genetic alterations of the TGF beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58(23): 5329-5332. (Pubitemid 28551110)
10. Hucl T. Molekulární patogeneze karcinomu pankreatu. Čes a Slov Ganstroent a Hepatol 2009; 63(2): 58-64.
11. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321(5897): 1801-1806.
12. Hucl T, Brody JR, Gallmeir E et al. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res 2007; 67(19): 9055-9065. (Pubitemid 47535890)
13. Zavoral M, Minarikova P, Zavada F et al. Molecular biology of pancreatic cancer. World J Gastroenterol 2011; 17(24): 2897-2908.
14. Vincent A, Herman J, Schulick R et al. Pancreatic cancer. Lancet 2011; 378(9791): 607-620.
15. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324(5933): 1457-1461.
16. Thomas AM, Santarsiero LM, Lutz ER et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo crosspriming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200(3): 297-306. (Pubitemid 39031249)
17. Kern SE, Shibata D. The fuzzy math of solid tumor stem cells. Cancer Res 2007; 67(19): 8985-8988. (Pubitemid 47535878)
18. Hidalgo M, Maitra A. The hedgehog path way and pancreatic cancer. N Engl J Med 2009; 361(21): 2094-2096.
19. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467(7319): 1114-1117.
20. Hruban RH, Adsaz NV, Albores-Saavedra J et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25(5): 579-586. (Pubitemid 32423354)
21. Hruban RH, Maitra A, Kern SE et al. Precursors to pancreatic cancer. Gastro enterol Clin North Am 2007; 36(4): 831-849. (Pubitemid 350051704)
22. Tanaka M, Fernandez-del Castillo C, Adsay V et al. International consensus guidelines 201 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12(3): 183-197.
23. Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4(6): 766-781. (Pubitemid 43825802)
24. Canto MI et al. Strategies for Screening for Pancreatic Adenocarcinoma in High-Risk Patients. Semin Oncol 2007; 34(4): 295-302. (Pubitemid 47176623)
25. Oliverius M, Kala Z, Varga M et al. Radical surgery for pancreatic malignancy in the elderly. Pancreatology 2010; 10(4): 499-502.
26. Van der GaaG NA, Rauws EA, van Eijck CH et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362(2): 129-137.
27. Laethem JL, Verslype C, Iovanna JL et al. New strategies and designs in pancrea tic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 2012; 23(3): 570-576.
28. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19): 1817-1825.
29. Hucl T, Rago C, Gallmeier E et al. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008; 68(13): 5023-5030.
30. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2007; 25(15): 1960-1966. (Pubitemid 46972777)